Drugs / IgM-enriched polyclonal immunoglobulins
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04182737 | May 2020 → Feb 2022 | immunodeficiency disease, infectious disease with sepsis | Massimo Girardis | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IgM-enriched polyclonal immunoglobulins | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04182737 ↗ |
| Known as | IgM preparation | “The treatment given to patients of both groups during this independent study will be the IgM-enriched immunoglobulin preparation (IgM preparation) (Pentaglobin®, Biotest,...” NCT04182737 ↗ |
| Modality | Protein / enzyme biologic | “additional therapy with polyclonal intravenous immunoglobulins may be a promising option in patients with septic shock.” PMID 33574139 ↗ Feb 2021 |
| Route | Intravenous | “additional therapy with polyclonal intravenous immunoglobulins may be a promising option in patients with septic shock.” PMID 33574139 ↗ Feb 2021 |